Agile Therapeutics, Inc.
AGRX
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.58M | 5.72M | 3.61M | 6.66M | 5.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.58M | 5.72M | 3.61M | 6.66M | 5.50M |
| Cost of Revenue | 1.50M | 1.68M | 2.19M | 2.48M | 2.31M |
| Gross Profit | 4.08M | 4.04M | 1.42M | 4.19M | 3.20M |
| SG&A Expenses | 6.29M | 6.30M | 5.42M | 7.48M | 7.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.32M | 8.47M | 7.67M | 10.66M | 10.63M |
| Operating Income | -2.75M | -2.76M | -4.05M | -4.00M | -5.13M |
| Income Before Tax | -11.87M | 1.28M | -4.47M | -799.00K | -3.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.87M | 1.28M | -4.47M | -799.00K | -3.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.87M | 1.28M | -4.47M | -799.00K | -3.81M |
| EBIT | -2.75M | -2.76M | -4.05M | -4.00M | -5.13M |
| EBITDA | -2.64M | -2.65M | -3.95M | -3.90M | -5.03M |
| EPS Basic | -1.73 | 0.28 | -1.51 | -0.27 | -2.15 |
| Normalized Basic EPS | -1.08 | 0.17 | -0.94 | -0.17 | -1.35 |
| EPS Diluted | -1.73 | 0.28 | -1.51 | -0.27 | -2.15 |
| Normalized Diluted EPS | -1.08 | 0.17 | -0.94 | -0.17 | -1.35 |
| Average Basic Shares Outstanding | 6.86M | 4.63M | 2.96M | 2.95M | 1.77M |
| Average Diluted Shares Outstanding | 6.86M | 4.63M | 2.96M | 2.95M | 1.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
